# ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

> **NCT03747328** · PHASE2 · WITHDRAWN · sponsor: **Aadi Bioscience, Inc.**

## Conditions studied

- Leigh Syndrome

## Interventions

- **DRUG:** ABI-009

## Key facts

- **NCT ID:** NCT03747328
- **Lead sponsor:** Aadi Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND withdrawn
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747328, "ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03747328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*